SCHEMBL10108786

SCHEMBL10108786

COc1cc(CC2c3cc(O)c(O)cc3CCN2C(C)(C)C)cc(OC)c1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXA2R P21731 2/20 0.61
▸ DRD1 P21728 3/20 0.55
▸ ADRB2 P07550 2/20 0.55
▸ ADRB1 P08588 2/20 0.55
▸ ADRB3 P13945 2/20 0.55
▸ HTR1A P08908 1/20 0.55
▸ ADRA2A P08913 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ OPRM1 P35372 1/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ DHFR P00374 1/20 0.55
▸ DRD2 P14416 2/20 0.52
▸ DRD4 P21917 1/20 0.49
▸ BCHE P06276 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8199189 0.84 DRD2 (0.71) TBXA2RDRD1ADRB2ADRB1ADRB3
SCHEMBL10747245 0.78 TBXA2R (0.57) TBXA2RDRD1ADRB2ADRB1ADRB3
SCHEMBL10745092 0.78 TBXA2R (0.57) TBXA2RDRD1ADRB2ADRB1ADRB3
SCHEMBL10341099 0.74 TBXA2R (0.53) TBXA2RDRD1ADRB2ADRB1ADRB3
SCHEMBL10341096 0.74 TBXA2R (0.53) TBXA2RDRD1ADRB2ADRB1ADRB3
SCHEMBL2112478 0.73 LMNA (0.81) DRD1DRD2BCHEKDM4EALDH1A1
SCHEMBL29837028 0.73 LMNA (0.81) DRD1DRD2BCHEKDM4EALDH1A1
SCHEMBL29748937 0.73 LMNA (0.81) DRD1DRD2BCHEKDM4EALDH1A1
SCHEMBL29924522 0.73 LMNA (0.81) DRD1DRD2BCHEKDM4EALDH1A1
Hydrochloric Acid SCHEMBL14691397 0.72 LMNA (0.79) DRD1DRD2BCHEKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 — — US disclosed
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 — — US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT TBXA2R 1211/4885DRD1 1649/4885ADRB2 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback